Our Platform

- Scalable solution for big data analysis in Healthcare

The BIOLYTICA platform offers a scalable solution for analysing big healthcare data, which includes the ability for users to pseudo-anonymize data conforming to EU regulations and the security measures, ensuring data analysis and storage on a secure cloud platform accessible only to users with the necessary access requirements. The platform can be offered with two user interfaces (UI). A research-oriented UI (R&D-UI) and a clinical decision support UI (CDS-UI). Both can be customized to the user’s needs. The platform has been developed for three scenarios, namely analysing next generation sequencing (NGS) and immunogenetics data, analysing monitoring data for Intensive Care Units (ICU) and analysing electronic health records (EHR) data for non-malignant chronic diseases such as diabetes.

Intensive Care Unit (ICU) applications

Intensive Care Unit (ICU) applications

For the ICU, a platform can be offered with a CDS-UI and an R&D-UI. The BIOLYTICA platform is developed using data from ventilation and biosignal monitors (i.e. heart rate variability) and offers accelerated (predictive) analytics for nutrition optimization, catheter related bloodstream infection (CRBSI), deterioration, ineffective efforts and high driving pressure.

 

Main benefits of the R&D-UI:

 

  • Several existing solutions offer local data storage and management whilst the Biolytica platform offers scalable, fast cloud-based storage and data management.
  • With the Biolytica platform, the patient data is pseudo-anonymized conforming to EU regulations prior to uploading.
  • The data of individual patients can be updated regularly, and this data can be used to improve and customize existing algorithms.
  • The R&D-UI offers an extensive package of analytics both descriptive and predictive.
  • Researchers have the ability to further improve and customize predictive analytics and present results using customized visualization tools.
  • All analyses can be accelerated which can result in faster results than current practice.
  • The analytics and visualisation tools can be used both for research purposes but also for generating quality metrics and gaining insight into the characteristics of the ICU population.
  • Other Platforms only include analytics for catheter-related bloodstream infection (CRBSI) and deterioration, however, the Biolytica platform also includes analyses of clusters of ineffective efforts (IEEVs), high driving pressure and nutrition optimisation.
 
 

Main benefits of the CDS-UI:

 

  • The Biolytica platform supports data from multichannel ICU monitors and ventilators.
  • The platform can provide real-time clinical decision support for identifying suboptimal nutrition, CRBSI, deterioration, and ineffective efforts. These results are then visualized on the local dashboard enabling the clinician to intervene.
  • The Biolytica platform analytics in the CDS-UI trigger a warning when IEEVs occur enabling the clinician to intervene.
  • Analytics in the CDS-UI aim to improve nutrition monitoring for ICU patients which may increase the percentage for whom the nutrition target is achieved with 0.34.
  • Using the electronic health record data, the CDS-UI can provide a risk score that a patient will develop catheter-related bloodstream infection (CRBSI). When the score of the patient is high, a clinician can replace the catheter and start treatment.
  • Combined, the analytics for IEEVs, nutrition and CRBSI hold the potential to save hospitals €2,557 and increase quality adjusted life years with 0.12 on average per patient.
 

Watch below the video recordings of the AEGLE Demonstration Webinar for (Clinical) Research and for Clinical Practice on the ICU use case:

 

 

ASK FOR DEMO

-->